West Pharmaceutical CEO buys more shares; Saudi Arabian pharma manufacturing to grow; NeuroVive does deal for South Korea;

> West Pharmaceutical Services ($WST) CEO Mark Green bought 18,300 shares of the company's stock at an average price of $54.89 per share last week in an open market transaction last week, giving him direct ownership of 18,300 shares. Article

> Spimaco's CEO, Fahad bin Ibrahim Al Khalaf, sees even greater growth of pharmaceutical manufacturing in Saudi Arabia in the coming years. Article

> NeuroVive Pharmaceutical said its Asia group has signed a deal with Sanofi's ($SNY) local affiliate to develop and market CicloMulsion in South Korea. Release

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.